Turning pancreatic cancer into a disease that the immune system can fight
Transforming Human Pancreatic Cancer Into An Immunologic Disease
This study is looking for ways to help the immune system better fight pancreatic cancer by creating stronger immune cells that can get into tumors and work more effectively, and it's for patients who are dealing with this tough condition.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11146678 on NIH RePORTER |
What this research studies
This research focuses on improving treatments for pancreatic ductal adenocarcinoma (PDA) by enhancing the immune system's ability to target and destroy cancer cells. The team aims to generate high-quality T cells that can effectively infiltrate tumors and overcome barriers that prevent immune responses. They will conduct both clinical studies with patients and pre-clinical studies using mouse models to test new therapies that modify the tumor environment and improve T cell function. The goal is to develop strategies that enable better immune responses against PDA, potentially leading to more effective treatments for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are seeking innovative treatment options.
Not a fit: Patients with other types of cancer or those who are not diagnosed with pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapies for pancreatic cancer, improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in using immunotherapy for other cancers, suggesting potential for success in similar approaches for pancreatic cancer.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Jaffee, Elizabeth M. — Johns Hopkins University
- Study coordinator: Jaffee, Elizabeth M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.